Post coronavirus disease 2019 condition in children at a children's hospital in Japan

Pediatr Int. 2023 Jan;65(1):e15458. doi: 10.1111/ped.15458.

Abstract

Background: Acute coronavirus disease 2019 (COVID-19) is associated with chronic symptoms. These have been termed the "post COVID-19 condition." The data on this condition in children are still limited. We therefore aimed to elucidate the characteristics of this post COVID-19 condition.

Methods: Children referred to a long COVID-19 clinic were included at Tokyo Metropolitan Children's Medical Center between October 2021 and July 2022. Children with another diagnosis and those who failed to meet criteria for post COVID-19 condition were excluded. Demographic and clinical data were collected retrospectively.

Results: Of 33 referrals, nine were excluded, and 24 fulfilled the criteria for post COVID-19 condition. The median age and percentage of girls were 12.5 (IQR: 11-13) years and 29.2%, respectively. All the patients had mild, acute COVID-19. Dysgeusia and brain fog was observed more frequently during the Delta and Omicron variant periods, respectively. School absenteeism >4 weeks was observed in 41.6% of the patients. Common symptoms included malaise, headache, dysgeusia, and dysosmia. The median duration of post COVID-19 condition was 4.5 (IQR: 2.8-5.2) months. Pain management and counseling using the pacing approach were the most commonly offered treatments. Symptom resolution and improvement was observed in 29.2% and 54.2% of the patients, respectively.

Conclusions: One third of the patients referred for long COVID did not fit the definition of the post COVID-19 condition. After a median follow up of 4.5 months, the majority of the cases resolved or improved.

Keywords: COVID-19; SARS-CoV-2; child; long COVID; post COVID-19 condition.

MeSH terms

  • COVID-19* / epidemiology
  • Child
  • Dysgeusia
  • Female
  • Hospitals
  • Humans
  • Japan / epidemiology
  • Post-Acute COVID-19 Syndrome
  • Retrospective Studies
  • SARS-CoV-2

Supplementary concepts

  • SARS-CoV-2 variants